Animal Pharm Antibiotics Sales

Animal Pharm Antibiotics Sales Market Outlook

The global Animal Pharm Antibiotics market is anticipated to reach USD 4.7 billion by 2035, with a compound annual growth rate (CAGR) of 5.6% during the forecast period of 2025 to 2035. The increasing demand for animal protein, coupled with rising concerns regarding animal health and productivity, is driving market growth. Additionally, the growing trend of pet ownership across various regions is augmenting the need for antibiotics in companion animals. Furthermore, significant advancements in veterinary healthcare and the development of novel antibiotic formulations are expected to contribute positively to the market dynamics. Regulatory reforms aimed at enhancing animal welfare and food safety standards will also play a crucial role in shaping the future landscape of this market. As the industry professionals continue to focus on sustainable and responsible antibiotic usage, the market is poised for substantial evolution in the years to come.

Growth Factor of the Market

The growth of the Animal Pharm Antibiotics market can be attributed to several interrelated factors that are reshaping the landscape of veterinary medicine. Firstly, the rising global population and the consequent demand for meat and dairy products are motivating farmers and producers to utilize antibiotics to enhance livestock health and productivity. Improved animal husbandry practices and increased investment in veterinary care are further driving the uptake of antibiotics aimed at managing and preventing diseases in livestock and companion animals alike. Additionally, the increasing incidence of zoonotic diseases has raised awareness about maintaining animal health, prompting veterinary professionals to prescribe antibiotics more judiciously. Furthermore, advancements in technology and pharmaceutical research are facilitating the development of more effective and targeted antibiotics, enabling the veterinary sector to address the unique health challenges faced by different animal species. This multifaceted growth trajectory is expected to sustain the market's upward momentum in the coming years.

Key Highlights of the Market

• The Animal Pharm Antibiotics market is projected to reach USD 4.7 billion by 2035, growing at a CAGR of 5.6% from 2025 to 2035.
• Rising pet ownership trends are significantly increasing the demand for antibiotics in companion animals.
• Technological advancements in drug formulation are leading to the introduction of innovative antibiotic solutions.
• Regulatory frameworks are increasingly focusing on responsible antibiotic use, impacting market practices.
• Livestock applications continue to dominate the market, driven by the need for enhanced productivity and disease management.

By Product Type

Cephalosporins:

Cephalosporins represent one of the key product types within the Animal Pharm Antibiotics market. These beta-lactam antibiotics are widely employed for their broad-spectrum activity against a variety of bacterial infections, making them particularly valuable in treating serious infections in both livestock and companion animals. Their effectiveness in combating resistant strains of bacteria is a major advantage, as it provides veterinarians with reliable treatment options for infections that may not respond to other antibiotics. Moreover, cephalosporins are increasingly being used in conjunction with other therapeutic agents to enhance treatment efficacy. With ongoing research focused on optimizing cephalosporin formulations for veterinary applications, this segment is expected to witness continued growth over the forecast period.

Penicillins:

Penicillins have long been a cornerstone in the treatment of bacterial infections in veterinary medicine. This antibiotic class is particularly favored due to its efficacy against a variety of gram-positive bacteria, which are commonly responsible for infections in both livestock and pets. The affordability and established safety profile of penicillins contribute to their widespread use in veterinary practices. Additionally, the development of penicillin derivatives has expanded their application to different animal species and infection types. As veterinary professionals become more aware of antibiotic resistance, the demand for penicillins—especially those with altered pharmacokinetics—is anticipated to grow, driven by their sustained effectiveness in managing infections.

Tetracyclines:

Tetracyclines are an important category of antibiotics used extensively in animal health for their broad-spectrum activity against many bacterial pathogens. These antibiotics work effectively to treat infections in livestock, particularly in swine and poultry, where respiratory infections and gastrointestinal diseases are prevalent. Tetracyclines are also increasingly utilized in companion animals to manage a variety of conditions, including periodontal disease and skin infections. Due to their unique mechanism of action, they are effective in combating drug-resistant bacteria. The increasing focus on improving animal welfare standards is likely to bolster the demand for tetracyclines, as veterinarians seek effective solutions for maintaining animal health.

Sulfonamides:

Sulfonamides are synthetic antibiotics that have been traditionally used in veterinary medicine for the treatment of a variety of bacterial infections. Their effectiveness in treating both systemic and localized infections makes them particularly useful in livestock and companion animals. Sulfonamides are often employed in combination therapies, enhancing their effectiveness while mitigating the development of resistance. The growing recognition of the importance of preventing disease outbreaks in livestock is expected to drive the use of sulfonamides, making them a significant player in the Animal Pharm Antibiotics market. Moreover, ongoing research into the optimal use of sulfonamides in veterinary settings will likely expand their application and effectiveness.

Aminoglycosides:

Aminoglycosides are another critical category of antibiotics in the veterinary sector, known for their potent activity against aerobic gram-negative bacteria. These antibiotics are particularly valuable when treating severe infections, especially in cases involving resistant bacterial strains. Aminoglycosides are commonly used in both livestock and companion animals for conditions such as urinary tract infections and septicemia. The unique pharmacokinetics of aminoglycosides, including their effectiveness in penetrating tissues, make them suitable for various therapeutic applications. As awareness of antibiotic stewardship increases, the role of aminoglycosides in targeted therapies is expected to gain prominence, thereby fostering growth in this segment.

By Application

Livestock:

The livestock segment constitutes a significant portion of the Animal Pharm Antibiotics market, driven by the necessity of maintaining the health and productivity of animals raised for food. The demand for antibiotics in livestock is primarily propelled by the need to prevent and control infectious diseases, which can have devastating impacts on herd health and productivity. Farmers increasingly recognize that healthy animals contribute to better growth rates, improved feed efficiency, and reduced mortality rates, thereby positively impacting profitability. The escalating global demand for meat and dairy products has further heightened the reliance on antibiotics for disease management in livestock. As regulatory bodies continue to emphasize responsible antibiotic usage, this segment is likely to experience further transformation, focusing on preventive health measures and alternative therapies.

Companion Animals:

The companion animal application segment is experiencing rapid growth, driven by the rising trend of pet ownership worldwide. Pet owners are increasingly concerned about the health and well-being of their animals, leading to greater utilization of veterinary services and medications, including antibiotics. Common health issues in dogs and cats, such as skin infections, dental diseases, and respiratory ailments, require effective antibiotic treatments to ensure quick recovery and the overall health of pets. Furthermore, the increasing willingness of pet owners to spend on healthcare services for their animals contributes to the growth of this market segment. As veterinarians advocate for regular health check-ups and preventive care, the significance of antibiotics in ensuring the well-being of companion animals is expected to remain substantial.

By Distribution Channel

Veterinary Hospitals:

Veterinary hospitals play a crucial role in the distribution of animal antibiotics, serving as primary healthcare facilities for both livestock and companion animals. These institutions are equipped with the necessary infrastructure and qualified professionals to diagnose and treat various health conditions, including infections requiring antibiotic intervention. The comprehensive services offered at veterinary hospitals, including diagnostics, surgeries, and emergency care, foster trust and reliability among pet owners and farmers alike. As the demand for specialized veterinary care continues to grow, the role of veterinary hospitals in dispensing antibiotics is expected to expand, supported by advancements in veterinary medicine and technology.

Veterinary Clinics:

Veterinary clinics are another essential distribution channel for animal antibiotics, serving as accessible healthcare options for pet owners and livestock producers. These clinics often provide a wide range of services, including routine check-ups, vaccinations, and treatment for common ailments, thus facilitating the timely administration of antibiotics when necessary. As veterinary clinics focus on delivering personalized care and building relationships with clients, the growth of this distribution channel is likely to continue. Additionally, the trend of mobile veterinary services is gaining further traction, enabling clinics to reach a more extensive client base, thereby enhancing access to antibiotics for a wider range of animals.

Online Pharmacies:

Online pharmacies have emerged as a vital distribution channel for animal antibiotics, particularly in an era characterized by digital transformation. With the increasing adoption of e-commerce, pet owners and livestock farmers now have the convenience of ordering medications from the comfort of their homes. Online pharmacies often provide competitive pricing, a broader selection of products, and the ability to access prescription medications without an in-person visit to a veterinary clinic. This convenience is especially appealing to pet owners who may live in remote or rural areas where access to veterinary services is limited. As the trend of online shopping continues to grow, the role of online pharmacies in distributing animal antibiotics is poised to expand significantly.

Retail Pharmacies:

Retail pharmacies are a traditional distribution channel for animal antibiotics, offering easy access to medications for both pet owners and livestock producers. These pharmacies often stock a variety of veterinary products, including antibiotics, anti-inflammatories, and nutritional supplements. The convenience of purchasing animal medications from local retail pharmacies is a significant advantage, particularly for pet owners seeking immediate solutions for their animals' health issues. Furthermore, as community pharmacies increasingly collaborate with local veterinarians to offer specialized veterinary services, the relevance of retail pharmacies in the distribution of animal antibiotics is likely to persist, ensuring that medications are readily available to support animal health.

By Ingredient Type

Enrofloxacin:

Enrofloxacin is a widely used antibiotic in veterinary medicine, particularly known for its broad-spectrum activity against various bacteria, including those causing respiratory and gastrointestinal infections in companion animals and livestock. Its efficacy in treating a range of conditions, along with its favorable pharmacokinetic properties, makes enrofloxacin a go-to choice for veterinarians. The increasing prevalence of resistant bacterial strains has led to a higher demand for enrofloxacin as a reliable therapeutic option. Moreover, ongoing research into optimizing dosing regimens and formulations is likely to enhance its application in veterinary practices, thereby contributing to its growth in the market.

Doxycycline:

Doxycycline is another essential ingredient in the development of antibiotics for animal health. This tetracycline antibiotic is recognized for its effectiveness against a variety of infections, including those caused by both gram-positive and gram-negative bacteria. Doxycycline is frequently used in dogs and cats for conditions like respiratory infections and tick-borne diseases. Its anti-inflammatory properties further enhance its therapeutic value in managing chronic diseases. The rising incidence of vector-borne diseases among companion animals, particularly in regions with significant flea and tick populations, is expected to drive the demand for doxycycline, establishing it as a critical component in the Animal Pharm Antibiotics market.

Amoxicillin:

Amoxicillin is a widely recognized antibiotic in veterinary medicine that belongs to the penicillin class. Known for its efficacy against a variety of bacterial infections, amoxicillin is frequently utilized in both livestock and companion animals to treat respiratory, urinary, and skin infections. Its user-friendly dosing regimen and established safety profile make it a preferred choice among veterinarians. Furthermore, the increasing awareness of pet health among owners contributes to the rise in demand for amoxicillin-based treatments. As veterinary practitioners continue to focus on judicious antibiotic use, the role of amoxicillin in promoting animal health is expected to grow significantly.

Tilmicosin:

Tilmicosin is a macrolide antibiotic widely used in veterinary medicine, particularly for its effectiveness in treating respiratory infections in livestock, especially in cattle and swine. Its unique formulation allows for prolonged therapeutic effects, making it an attractive option for livestock producers seeking to manage outbreaks of pneumonia and other respiratory diseases. The increasing focus on maintaining herd health and productivity, coupled with rising awareness of the economic impact of infections in livestock, is expected to drive the demand for tilmicosin. As veterinary professionals continue to seek effective solutions for managing common health issues in livestock, the importance of tilmicosin in the market is likely to persist and expand.

Florfenicol:

Florfenicol is a broad-spectrum antibiotic commonly employed in veterinary medicine, particularly known for its efficacy against respiratory infections in livestock. Its unique formulation allows for effective treatments without the risk of antibiotic residues in food products, making it a preferred option for food-producing animals. The growing emphasis on food safety and quality in the livestock sector is expected to drive the demand for florfenicol, as producers prioritize responsible antibiotic use. Additionally, florfenicol's effectiveness against resistant bacterial strains positions it as a vital tool in the ongoing fight against antimicrobial resistance in veterinary medicine, contributing to its sustained relevance in the Animal Pharm Antibiotics market.

By Region

The Animal Pharm Antibiotics market exhibits varied dynamics across different regions, each characterized by unique growth drivers and challenges. North America holds a prominent position in the market, accounting for approximately 30% of the total share, driven by the high demand for animal protein and the extensive use of antibiotics in both livestock and companion animals. The stringent regulatory environment regarding antibiotic use and the increasing focus on veterinary care are expected to influence market growth positively. Moreover, the growing trend of pet ownership in the U.S. and Canada is further bolstering the demand for animal antibiotics. The CAGR for this region is forecasted at 6.2%, showcasing robust growth potential as the veterinary sector continues to evolve.

On the other hand, the Asia Pacific region is anticipated to witness significant growth in the Animal Pharm Antibiotics market, primarily due to the rapid expansion of the livestock industry and increasing urbanization. This region is projected to account for approximately 25% of the market share, with countries such as China and India emerging as key players in veterinary healthcare. The rising income levels and changing dietary habits among consumers are driving the demand for meat and dairy products, subsequently increasing the reliance on antibiotics for disease prevention and treatment. The CAGR for the Asia Pacific market is estimated at 7.1%, reflecting a strong upward trend driven by advancements in veterinary medicine and a growing awareness of animal health.

Opportunities

The Animal Pharm Antibiotics market presents numerous opportunities for stakeholders and new entrants alike. One of the most significant opportunities lies in the development of novel antibiotic formulations that target specific pathogens while minimizing the risk of resistance. With the growing prevalence of antimicrobial resistance, the need for innovative approaches to antibiotic development is more critical than ever. Research institutions and pharmaceutical companies are increasingly collaborating to explore alternatives to traditional antibiotics, such as bacteriophages and immunotherapies. This focus on innovation opens doors for companies to differentiate themselves in a competitive market by offering unique, effective solutions for animal health.

Another opportunity is the expansion of telemedicine and online veterinary services, which provide pet owners and livestock producers with greater access to veterinary care. As more consumers turn to digital platforms for purchasing medications and seeking veterinary advice, businesses that leverage technology to enhance accessibility and convenience will thrive. This trend also creates prospects for educational initiatives aimed at promoting responsible antibiotic use and ensuring that consumers are well-informed about the medications they administer to their animals. By capitalizing on these trends, companies can position themselves to meet the evolving needs of the market while contributing to the overall improvement of animal health standards.

Threats

Despite the positive outlook for the Animal Pharm Antibiotics market, several threats could impede its growth trajectory. One of the primary concerns is the increasing prevalence of antibiotic resistance, which poses a significant challenge to veterinary medicine. The overuse and misuse of antibiotics in both livestock and companion animals are contributing to the emergence of resistant bacterial strains, diminishing the effectiveness of existing antibiotics. This situation not only threatens animal health but also raises concerns about food safety and human health, as resistant bacteria can be transmitted through the food chain. As regulatory authorities around the world tighten restrictions on antibiotic use, veterinary professionals must adapt to these changes, potentially resulting in reduced market access for certain antibiotic products.

Another significant threat to the market is the growing emphasis on alternative therapies and preventive measures in animal healthcare. As consumers become more aware of the risks associated with antibiotic use, there is a rising demand for organic and natural products, as well as solutions that focus on maintaining animal health through nutrition and hygiene practices. This shift towards holistic approaches could challenge the traditional reliance on antibiotics, necessitating a reevaluation of product portfolios and marketing strategies among industry players. Companies must stay attuned to these changing consumer preferences and invest in research and development to develop innovative, effective alternatives that complement existing antibiotic treatments.

Competitor Outlook

• Zoetis
• Merck Animal Health
• Elanco Animal Health
• Ceva Santé Animale
• Virbac
• Norbrook Laboratories
• Boehringer Ingelheim
• Phibro Animal Health Corporation
• Dechra Pharmaceuticals
• Huvepharma
• Vetmedin
• Cegelec
• Vetoquinol
• Intervet
• Intas Pharmaceuticals

The competitive landscape of the Animal Pharm Antibiotics market is characterized by a multitude of established players and emerging companies, each striving to enhance their market position through innovative product offerings and strategic collaborations. Major companies such as Zoetis, Merck Animal Health, and Elanco Animal Health are leading the charge, investing heavily in research and development to expand their antibiotic portfolios and address the growing challenge of antimicrobial resistance. These key players are also focusing on acquiring smaller companies to enhance their capabilities and broaden their product ranges, thereby fortifying their competitive edge in the market.

Zoetis, one of the largest animal health companies globally, has a comprehensive portfolio of antibiotics and is committed to research aimed at developing effective solutions for both livestock and companion animals. Merck Animal Health remains a formidable presence in the market, with a focus on delivering high-quality animal health products. Their commitment to sustainability and responsible antibiotic use is evident in their ongoing initiatives to educate veterinarians and pet owners about prudent antibiotic practices. Meanwhile, Elanco Animal Health is continuously innovating its product offerings to meet the evolving demands of the veterinary sector, placing a significant emphasis on developing alternatives to traditional antibiotics.

Emerging companies, such as Huvepharma and Intas Pharmaceuticals, are carving out their own niches in the Animal Pharm Antibiotics market. These companies are leveraging the growing demand for veterinary antibiotics in developing regions, where livestock production is expanding rapidly. By focusing on affordability and accessibility, these emerging players are poised to make significant inroads in the market. Furthermore, collaborations between pharmaceutical companies and research institutions are paving the way for the development of innovative antibiotic solutions, ensuring that the market remains dynamic and responsive to the ongoing challenges in animal healthcare.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Virbac
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Zoetis
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Cegelec
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Intervet
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Vetmedin
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Huvepharma
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Vetoquinol
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck Animal Health
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Boehringer Ingelheim
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Elanco Animal Health
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Intas Pharmaceuticals
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Norbrook Laboratories
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Dechra Pharmaceuticals
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Ceva Santé Animale
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Phibro Animal Health Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Animal Pharm Antibiotics Sales Market, By Application
    • 6.1.1 Livestock
    • 6.1.2 Companion Animals
  • 6.2 Animal Pharm Antibiotics Sales Market, By Product Type
    • 6.2.1 Cephalosporins
    • 6.2.2 Penicillins
    • 6.2.3 Tetracyclines
    • 6.2.4 Sulfonamides
    • 6.2.5 Aminoglycosides
  • 6.3 Animal Pharm Antibiotics Sales Market, By Ingredient Type
    • 6.3.1 Enrofloxacin
    • 6.3.2 Doxycycline
    • 6.3.3 Amoxicillin
    • 6.3.4 Tilmicosin
    • 6.3.5 Florfenicol
  • 6.4 Animal Pharm Antibiotics Sales Market, By Distribution Channel
    • 6.4.1 Veterinary Hospitals
    • 6.4.2 Veterinary Clinics
    • 6.4.3 Online Pharmacies
    • 6.4.4 Retail Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Animal Pharm Antibiotics Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Animal Pharm Antibiotics Sales market is categorized based on

By Product Type

• Cephalosporins
• Penicillins
• Tetracyclines
• Sulfonamides
• Aminoglycosides

By Application

• Livestock
• Companion Animals

By Distribution Channel

• Veterinary Hospitals
• Veterinary Clinics
• Online Pharmacies
• Retail Pharmacies

By Ingredient Type

• Enrofloxacin
• Doxycycline
• Amoxicillin
• Tilmicosin
• Florfenicol

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Zoetis
• Merck Animal Health
• Elanco Animal Health
• Ceva Santé Animale
• Virbac
• Norbrook Laboratories
• Boehringer Ingelheim
• Phibro Animal Health Corporation
• Dechra Pharmaceuticals
• Huvepharma
• Vetmedin
• Cegelec
• Vetoquinol
• Intervet
• Intas Pharmaceuticals